J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.

Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Hims & Hers Health is down ~3% in Friday morning trading after an analyst note from BofA Securities stated that the company's ...

The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

In the fourth quarter of 2024, the Baird Chautauqua International Growth Fund Net Investor Class returned -4.31%, ...

Hims & Hers (HIMS) is down -6.5%, or -$1.81 to $26.13.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with Top ...

On the macro front, building permits decreased by 0.7% month-on-month in December to a seasonally adjusted rate of 1.48m, ...

In the third quarter of 2024, sustainable open-end and exchange-traded funds witnessed a surge in net new money, drawing in an estimated USD 10.4 billion. This represents a significant increase ...